The current discussion of downstream bottlenecks arises from the ease with which up-stream activities generate protein and the desire for downstream operations to match upstream productivity. “In ...

Upstream titers of 3–5 g/L, and up to 10–13 g/L, are outpacing downstream capacity, creating chromatography, filtration, and UF/DF throughput bottlenecks that elevate cost and delay timelines. Complex ...

Biopharmaceutical manufacturing involves a balancing act between the capacity of cell culture and downstream purification. Balancing the two has always been difficult because construction decisions ...

James Chen, CMT is an expert trader, investment adviser, and global market strategist. Thomas J. Brock is a CFA and CPA with more than 20 years of experience in various areas including investing, ...

Biologics technology transfer (tech transfer) requires close coordination across every step, from initial process definition, subsequent analytical interpretation, and cross-facility execution.